Background and study aim : Monitoring of liver fibrosis progression is important in patients with chronic hepatitis C .The aim of this study is to verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C compared with other noninvasive tests. Patients and methods: This study included 90 naïve patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treat­ment and 20 healthy volunteers as a control group. FibroQ, aspartate aminotransferase (AST)/ala­nine amino-transferase ratio (AAR), AST to platelet ratio index, cirrhosis discriminates score, age-platelet index (API), Pohl score, FIB-4 index, and Lok's model were calculated and compared. Results: FibroQ, FIB-4, AAR, API and Lok's model results increased significantly as fibrosis advanced .FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests. Conclusion: FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.